Personalis, Inc.

PSNL Healthcare Diagnostics & Research

Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS fell 30.4% and free cash flow fell 123.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

15.65 0.28 −1.76%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.5×
Dividend yield
—
F-score
4/9
Altman Z
3.35
Beneish M
−1.30
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
4 6 4 2 4 3 — — —
Altman Z-Score
3.35 0.45 (3.04) (1.39) 4.03 14.73 1.70 — —
P/S ratio
10.20 4.05 1.34 1.41 7.33 16.00 3.01 0.00 0.00
Altman Z″-Score (non-manufacturers)
0.31 (0.99) (5.75) 0.14 5.39 5.35 2.08 (16.47) —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
(1.30) (3.56) (3.88) (3.01) (0.03) (0.99) (2.21) — —
P/Operating CF
(31.93) (43.93) (7.32) (5.48) (41.00) (497.03) 81.63 1,334.41 1,334.41
P/B ratio
2.72 1.69 0.76 0.42 2.02 6.46 1.84 0.00 0.00
Price to Tangible BV
2.72 1.69 0.76 0.42 2.02 6.46 1.84 0.00 0.00
EV/Sales
7.01 2.07 0.03 (0.89) 4.18 13.65 1.32 0.00 0.00
EV/EBITDA
0.00 0.00 0.00 0.54 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(6.52) (3.89) (0.04) 0.82 (5.04) (25.16) (4.76) 12.12 12.12
EV/FCF
(6.15) (3.77) (0.03) 0.48 (4.36) (23.38) (3.25) (21.53) (21.53)
Quick Ratio
6.46 6.21 2.79 5.56 9.76 5.16 2.63 0.42 0.50
Current Ratio
6.76 6.52 3.11 6.03 10.16 5.43 2.79 0.51 0.53
Net Debt/EBITDA
2.93 3.08 1.13 1.57 5.01 5.65 7.24 1.84 1.08
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.23 0.34 0.28 0.19 0.27 0.39 0.66 1.81 0.25
Operating CF/Net income
0.92 0.56 0.52 0.62 1.09 1.03 0.72 (0.28) (0.01)
Capex/Depreciation
(0.74) (0.16) (1.17) (5.88) (1.38) (0.53) (1.78) (2.56) (4.24)
Interest Coverage
(429.55) (2,844.46) (999.42) (574.78) (355.18) (21,073.00) (19.79) (7.27) (17.01)
ROE
(35.02%) (48.91%) (62.31%) (42.89%) (25.82%) (27.37%) (16,611.92%) 19.99% 23.72%
ROA
(26.89%) (32.82%) (41.83%) (32.88%) (20.34%) (20.53%) (25.21%) (95.45%) (62.73%)
ROIC
(259.21%) (237.72%) (450.20%) (143.04%) (175.78%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(29.75%) (36.92%) (69.03%) (49.59%) (21.28%) (21.51%) (24.18%) 118.09% 143.35%
Average Days of Receivables
84.91 35.11 88.07 93.38 78.85 29.47 18.47 43.07 75.27
Research and Development Expense of Revenue
72.17% 57.80% 88.15% 99.79% 57.68% 36.32% 34.38% 37.87% 105.60%
Selling, General and Administrative Expense of Revenue
76.92% 54.59% 67.67% 98.34% 55.79% 42.84% 33.86% 29.84% 105.41%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
13.54% 12.63% 19.12% 29.88% 16.82% 10.47% 7.45% 3.49% 8.02%
Graham Net Nets
0.27 0.40 0.52 1.36 0.37 0.14 0.45 0.34 0.34
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(11.43%) (23.70%) (110.29%) (123.38%) (10.37%) (3.25%) (28.98%) (4.91%) (4.91%)
Free Cash Flow Yield
(11.18%) (13.58%) (68.35%) (130.76%) (13.08%) (3.65%) (13.47%) (3.60%) (3.60%)
Revenue per Share
0.78 1.43 1.53 1.42 1.95 2.29 3.62 12.33 3.10
Operating CF per Share
(0.84) (0.76) (1.17) (1.54) (1.61) (1.24) (1.00) 1.82 0.10
Capex per Share
(0.05) (0.02) (0.23) (1.09) (0.25) (0.09) (0.47) (2.56) (1.70)
Free Cash Flow per Share
(0.89) (0.78) (1.39) (2.63) (1.87) (1.34) (1.47) (0.74) (1.61)
Cash per Share
2.69 3.12 2.37 3.67 6.54 5.91 7.12 6.45 7.46
Shareholders Equity per Share
2.93 3.43 2.69 4.77 7.07 5.67 5.92 (34.73) 0.00
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
2.93 3.43 2.69 4.77 7.07 5.67 5.92 (34.73) 0.00
Free Cash Flow
(79.45) (46.51) (67.17) (120.13) (81.91) (45.90) (26.45) (2.28) (4.87)
Working Capital
228.32 171.89 99.51 166.57 286.92 180.08 89.62 (28.29) (22.80)
Capital Expenditures
(4.50) (1.36) (10.91) (49.90) (11.08) (3.25) (8.38) (7.85) (5.16)
Net Current Asset Value
194.97 135.70 51.09 125.14 232.00 170.82 88.98 (118.50) 26.18
EV/EBIT
0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.06 0.02 0.15 0.77 0.13 0.04 0.13 0.21 0.55
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.14 0.17 0.16 0.14 0.41 0.52 0.33 0.27 0.19
Cash ROIC
(15.85%) (11.99%) (27.57%) (31.14%) (13.71%) (11.53%) (11.26%) 2.63% (21.52%)
Accounts Receivable Turnover
5.72 6.54 4.28 3.71 6.89 16.30 16.81 11.82 2.94
Accounts Payable Turnover
5.56 5.42 3.98 4.68 6.15 7.49 6.20 4.90 2.21
Inventory Turnover
8.92 7.04 5.80 7.28 9.57 11.43 10.73 12.21 7.94
Average Days of Payables
88.01 40.40 98.53 90.75 62.52 51.76 62.10 92.27 125.49
Days of Inventory on Hand
41.63 37.51 69.17 60.66 38.03 35.16 38.98 48.24 25.56
Average Receivables
12.17 12.94 17.19 17.56 12.41 4.82 3.88 3.20 3.20
Average Payables
9.69 10.66 13.89 11.04 8.76 7.82 6.95 5.30 5.30
Average Inventory
6.04 8.21 9.53 7.10 5.62 5.12 4.02 2.13 1.48
Average Assets
302.22 247.68 258.90 344.61 320.69 201.07 99.48 20.84 37.62
Average Common Equity
232.07 166.20 173.79 264.22 252.62 150.82 0.15 (99.50) (99.50)

Fold the line items

Columns are period end dates